Using glucagon receptor antagonism to evaluate the physiological effects of extrapancreatic glucagon in totally pancreatectomised individuals: a randomised controlled trial
This study was supported by grants from the Aase and Ejnar Danielsen's Foundation and the Novo Nordisk Foundation.
Authors
- Tina Vilsbøll (ORCID: https://orcid.org/0000-0002-0456-6787)
- Gerrit van Hall (ORCID: https://orcid.org/0000-0002-2519-8127)
- Flemming Dela (ORCID: https://orcid.org/0000-0001-9970-9535)
- METTE MARIE ROSENKILDE (ORCID: https://orcid.org/0000-0001-9600-3254)
- Carsten Palnæs Hansen (ORCID: https://orcid.org/0000-0002-9256-2240)
- Nicolai J. Wewer Albrechtsen (ORCID: https://orcid.org/0000-0003-4230-5753)
- Bolette Hartmann (ORCID: https://orcid.org/0000-0001-8509-2036)
- Asger Lund (ORCID: https://orcid.org/0000-0003-1212-3764)
- Filip K. Knop (ORCID: https://orcid.org/0000-0002-2495-5034)
- Camilla J. Kibsgaard
- Jens Juul Holst (ORCID: https://orcid.org/0000-0001-6853-3805)
- Maria M. Andersen
- Sofie Hædersdal (ORCID: https://orcid.org/0000-0002-2393-5947)
- Caroline Trunk‐Black Juel
- Jan Henrik Storkholm
Institutions
- University of Copenhagen (DK)
- Steno Diabetes Centers (DK)
- Novo Nordisk (Denmark) (DK)
- Novo Nordisk Foundation (DK)
- Frederiksberg Hospital (DK)
- Copenhagen University Hospital (DK)
- Gentofte Hospital (DK)
- Rigshospitalet (DK)
Publication Details
- Journal
- Diabetologia
- Published
- 2025-09-18
- DOI
- https://doi.org/10.1007/s00125-025-06534-z
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- Gentofte Hospital
- Novo Nordisk